BAXTER INTERNATIONAL INC
BAXAPI behind this page
BAX Q3 2025 request
Playground key active
/api/financials?ticker=BAX&year=2025&quarter=3
Pick an endpoint and run the request.Income Statement
| Metric | Q3 2025 | Q3 2024 | YoY |
|---|---|---|---|
| Revenue | 2,835 | 2,699 | +5.0% |
Show Product Lines breakouts |
|||
| Advanced Surgery · Medical Products & Therapies | 168 | 149 | +12.8% |
| Advanced Surgery · Medical Products & Therapies | 138 | 123 | +12.2% |
| Advanced Surgery · Medical Products & Therapies | 306 | 272 | +12.5% |
| Care & Connectivity Solutions · Healthcare Systems & Technologies | 348 | 335 | +3.9% |
| Care & Connectivity Solutions · Healthcare Systems & Technologies | 125 | 121 | +3.3% |
| Care & Connectivity Solutions · Healthcare Systems & Technologies | 473 | 456 | +3.7% |
| Drug Compounding · Pharmaceuticals | 299 | 267 | +12.0% |
| Drug Compounding · Pharmaceuticals | 299 | 267 | +12.0% |
| Front Line Care · Healthcare Systems & Technologies | 229 | 222 | +3.2% |
| Front Line Care · Healthcare Systems & Technologies | 71 | 74 | -4.1% |
| Front Line Care · Healthcare Systems & Technologies | 300 | 296 | +1.4% |
| Infusion Therapies & Technologies · Medical Products & Therapies | 555 | 613 | -9.5% |
| Infusion Therapies & Technologies · Medical Products & Therapies | 468 | 457 | +2.4% |
| Infusion Therapies & Technologies · Medical Products & Therapies | 1,023 | 1,070 | -4.4% |
| Injectables & Anesthesia · Pharmaceuticals | 177 | 178 | -0.6% |
| Injectables & Anesthesia · Pharmaceuticals | 156 | 143 | +9.1% |
| Injectables & Anesthesia · Pharmaceuticals | 333 | 321 | +3.7% |
Show Business Segments breakouts |
|||
| Healthcare Systems & Technologies · Non Us | 196 | 195 | +0.5% |
| Healthcare Systems & Technologies · Operating Segments | 773 | 752 | +2.8% |
| Healthcare Systems & Technologies · US | 577 | 557 | +3.6% |
| Medical Products & Therapies · Non Us | 606 | 580 | +4.5% |
| Medical Products & Therapies · Operating Segments | 1,329 | 1,342 | -1.0% |
| Medical Products & Therapies · US | 723 | 762 | -5.1% |
| Pharmaceuticals · Non Us | 455 | 410 | +11.0% |
| Pharmaceuticals · Operating Segments | 632 | 588 | +7.5% |
| Pharmaceuticals · US | 177 | 178 | -0.6% |
Show Geography breakouts |
|||
| Emerging Markets | 355 | 347 | +2.3% |
| Non Us | 1,291 | 1,199 | +7.7% |
| Non Us · Corporate Non Segment | 34 | 14 | +142.9% |
| Rest of world | 936 | 852 | +9.9% |
| US | 1,544 | 1,500 | +2.9% |
| US · Corporate Non Segment | 67 | 3 | +2133.3% |
Show Consolidation Items breakouts |
|||
| Corporate Non Segment | 101 | 17 | +494.1% |
| Cost of Revenue | 1,885 | 1,666 | +13.1% |
Show Business Segments breakouts |
|||
| Healthcare Systems & Technologies · Operating Segments | 410 | 368 | +11.4% |
| Medical Products & Therapies · Operating Segments | 752 | 734 | +2.5% |
| Pharmaceuticals · Operating Segments | 450 | 408 | +10.3% |
Show Equity Components breakouts |
|||
| Accumulated Gain Loss Net Cash Flow Hedge Parent · Interest Rate Contract | 1 | — | — |
| Gross Profit | 950 | 1,033 | -8.0% |
| Research & Development | 118 | 129 | -8.5% |
Show Business Segments breakouts |
|||
| Healthcare Systems & Technologies · Operating Segments | 48 | 45 | +6.7% |
| Medical Products & Therapies · Operating Segments | 41 | 53 | -22.6% |
| Pharmaceuticals · Operating Segments | 26 | 23 | +13.0% |
| Selling, General & Administrative | 708 | 754 | -6.1% |
Show Business Segments breakouts |
|||
| Healthcare Systems & Technologies · Operating Segments | 219 | 203 | +7.9% |
| Medical Products & Therapies · Operating Segments | 286 | 291 | -1.7% |
| Pharmaceuticals · Operating Segments | 107 | 95 | +12.6% |
| Operating Income | 172 | 155 | +11.0% |
Show Business Segments breakouts |
|||
| Healthcare Systems & Technologies · Operating Segments | 104 | 136 | -23.5% |
| Medical Products & Therapies · Operating Segments | 273 | 268 | +1.9% |
| Pharmaceuticals · Operating Segments | 56 | 58 | -3.4% |
| Reportable Segment · Operating Segments | 433 | 462 | -6.3% |
| Interest Expense | -10 | -14 | +28.6% |
| Other Non-Operating Income (Expense) | 7 | 1 | +600.0% |
Show Equity Components breakouts |
|||
| Accumulated Defined Benefit Plans Adjustment · Reclassification Out Of Accumulated Other Comprehensive Income | 3 | 1 | +200.0% |
| Income Before Taxes | 121 | 69 | +75.4% |
| Income Tax Expense (Benefit) | 172 | 8 | +2050.0% |
| Net Income | -46 | 140 | -132.9% |
Show Equity Components breakouts |
|||
| Accumulated Defined Benefit Plans Adjustment · Reclassification Out Of Accumulated Other Comprehensive Income | 3 | — | — |
| Accumulated Gain Loss Net Cash Flow Hedge Parent · Reclassification Out Of Accumulated Other Comprehensive Income | -1 | 2 | -150.0% |
Show Reclassification Out Of Accumulated Other Comprehensive Income breakouts |
|||
| Reclassification Out Of Accumulated Other Comprehensive Income | 2 | 3 | -33.3% |
| Comprehensive Income | -33 | 321 | -110.3% |
| EPS (Basic) | -0.09 | 0.27 | -133.3% |
| EPS (Diluted) | -0.09 | 0.27 | -133.3% |
| Wtd Avg Shares (Basic) | 514 | 510 | +0.8% |
| Wtd Avg Shares (Diluted) | 514 | 512 | +0.4% |
| Operating Lease Lease Income | 86 | 102 | -15.7% |
| Other Expenses (Q) | — | — | — |
Show Business Segments breakouts |
|||
| Healthcare Systems & Technologies · Operating Segments | -8 | — | — |
| Medical Products & Therapies · Operating Segments | -23 | -4 | -475.0% |
| Pharmaceuticals · Operating Segments | -7 | 4 | -275.0% |
Balance Sheet
| Metric | Q3 2025 | Q3 2024 | YoY |
|---|---|---|---|
| Current Assets | |||
| Cash & Cash Equivalents | 1,726 | 1,420 | +21.5% |
| Accounts Receivable | 1,777 | 1,729 | +2.8% |
| Inventory | 2,460 | 2,103 | +17.0% |
| Prepaid Expenses & Other Current Assets | 970 | 720 | +34.7% |
| Total Current Assets | 6,933 | 8,864 | -21.8% |
| Non-Current Assets | |||
| Property, Plant & Equipment | 2,812 | 2,833 | -0.7% |
| Goodwill | 5,400 | 5,783 | -6.6% |
Show Business Segments breakouts |
|||
| Healthcare Systems & Technologies | 3,570 | 3,989 | -10.5% |
| Medical Products & Therapies | 1,257 | 1,234 | +1.9% |
| Pharmaceuticals | 573 | 560 | +2.3% |
| Operating Lease Right-of-Use Assets | 270 | 327 | -17.4% |
| Other Non-Current Assets | 847 | 886 | -4.4% |
| Total Assets | 21,067 | 26,676 | -21.0% |
| Intangible Assets (Q) | — | — | — |
Show Finite Lived Intangible Assets By Major Class breakouts |
|||
| Customer Relationships | 2,352 | 2,566 | -8.3% |
| Developed technology, including patents | 848 | 1,155 | -26.6% |
| Other Intangible Assets | 19 | 20 | -5.0% |
| Trade Names | 799 | 871 | -8.3% |
| Other Assets | |||
| Intangible Assets Net Excluding Goodwill | 4,805 | 5,449 | -11.8% |
| Current Liabilities | |||
| Short Term Borrowings | 4 | — | — |
| Long Term Debt And Capital Lease Obligations Current | 751 | 2,498 | -69.9% |
| Accounts Payable | 953 | 841 | +13.3% |
| Accrued Liabilities | 2,067 | 1,772 | +16.6% |
| Total Current Liabilities | 3,775 | 6,200 | -39.1% |
| Non-Current Liabilities | |||
| Operating Lease Liabilities | 210 | 259 | -18.9% |
| Other Non-Current Liabilities | 1,121 | 1,263 | -11.2% |
| Total Liabilities | 13,853 | 18,734 | -26.1% |
| Other Liabilities | |||
| Long Term Debt And Lease Obligation Excluding Current Maturities | 8,747 | — | — |
| Stockholders' Equity | |||
| Common Stock | 683 | 683 | 0.0% |
| Treasury Stock Common Value | -10,891 | -11,084 | +1.7% |
| Additional Paid In Capital Common Stock | 6,345 | 6,391 | -0.7% |
| Retained Earnings | 14,837 | 15,529 | -4.5% |
| Accumulated Other Comprehensive Income | -3,733 | -3,647 | -2.4% |
| Total Stockholders' Equity | 7,241 | 7,872 | -8.0% |
| Minority Interest | -27 | 70 | -138.6% |
| Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 7,214 | 7,942 | -9.2% |
Show Equity Components breakouts |
|||
| Accumulated Defined Benefit Plans Adjustment | -481 | -455 | -5.7% |
| Accumulated Gain Loss Net Cash Flow Hedge Parent | -110 | -118 | +6.8% |
| Accumulated Net Unrealized Investment Gain Loss | 3 | 3 | 0.0% |
| Accumulated Other Comprehensive Income | -3,733 | -3,647 | -2.4% |
| Accumulated Translation Adjustment | -3,145 | -3,077 | -2.2% |
| Additional Paid In Capital | 6,345 | 6,391 | -0.7% |
| Common Stock | 683 | 683 | 0.0% |
| Noncontrolling Interest | -27 | 70 | -138.6% |
| Parent | 7,241 | 7,872 | -8.0% |
| Retained Earnings | 14,837 | 15,529 | -4.5% |
| Treasury Stock Common | -10,891 | -11,084 | +1.7% |
| Total Liabilities & Equity | 21,067 | 26,676 | -21.0% |
Cash Flow Statement
| Metric | YTD Q3 2025 | YTD Q3 2024 | YoY |
|---|---|---|---|
| Operating Activities | |||
| Net Income | 171 | -128 | +233.6% |
Show Equity Components breakouts |
|||
| Parent | 171 | -137 | +224.8% |
| Retained Earnings | 171 | -137 | +224.8% |
| Income Loss From Discontinued Operations Net Of Tax | 36 | -290 | +112.4% |
Show Equity Components breakouts |
|||
| Accumulated Defined Benefit Plans Adjustment · Reclassification Out Of Accumulated Other Comprehensive Income | -14 | — | — |
| Accumulated Translation Adjustment · Reclassification Out Of Accumulated Other Comprehensive Income | -126 | — | — |
Show Disposal Group Classification breakouts |
|||
| Discontinued Operations Disposed Of By Sale | 36 | -290 | +112.4% |
| Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest | 135 | 162 | -16.7% |
| Depreciation & Amortization | 741 | 752 | -1.5% |
| Deferred Income Taxes And Tax Credits | -115 | -136 | +15.4% |
| Stock-Based Compensation | 80 | 75 | +6.7% |
| Pension And Other Postretirement Benefits Expense Reversal Of Expense Noncash | -24 | -21 | -14.3% |
| Other Asset Impairment Charges | 24 | 42 | -42.9% |
| Other Non-Cash Items | 22 | 20 | +10.0% |
| Change in Accounts Receivable | -44 | -17 | -158.8% |
| Change in Inventory | -360 | -180 | -100.0% |
| Change in Prepaid & Other Assets | -32 | -61 | +47.5% |
| Change in Accounts Payable | -36 | 3 | -1300.0% |
| Increase Decrease In Accrued Expenses And Other Current Liabilities | 31 | -192 | +116.1% |
| Other Operating Activities Cash Flow Statement | -67 | -71 | +5.6% |
| Net Cash Provided By Used In Operating Activities Continuing Operations | 355 | 376 | -5.6% |
| Cash Provided By Used In Operating Activities Discontinued Operations | -94 | 155 | -160.6% |
| Net Cash from Operations | 261 | 531 | -50.8% |
| Investing Activities | |||
| Payments To Acquire Other Productive Assets | -373 | -314 | -18.8% |
| Payments To Acquire Intangible Assets | -9 | -9 | 0.0% |
| Other Investing Activities | 32 | 8 | +300.0% |
| Net Cash Provided By Used In Investing Activities Continuing Operations | -350 | -281 | -24.6% |
| Cash Provided By Used In Investing Activities Discontinued Operations | 3,389 | -140 | +2520.7% |
| Net Cash from Investing | 3,039 | -421 | +821.9% |
| Financing Activities | |||
| Debt Repayments | -3,505 | -827 | -323.8% |
| Proceeds From Repayments Of Short Term Debt Maturing In Three Months Or Less | -300 | — | — |
| Payments Of Dividends Common Stock | -261 | -443 | +41.1% |
| Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options | 25 | 63 | -60.3% |
| Payment For Contingent Consideration Liability Financing Activities | -10 | — | — |
| Proceeds From Payments For Other Financing Activities | -18 | -15 | -20.0% |
| Net Cash from Financing | -4,069 | -1,222 | -233.0% |
| Supplemental | |||
| Unpaid Capital Expenditures (YTD) | — | — | — |
Show Property Plant And Equipment By Type breakouts |
|||
| Property Plant And Equipment | 45 | 34 | +32.4% |
| Other Cash Flow | |||
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 83 | -45 | +284.4% |
| Net Change in Cash | -686 | -1,118 | +38.6% |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | 1,728 | 2,080 | -16.9% |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 1,728 | 1,422 | +21.5% |
Values in millions USD. Source: SEC EDGAR 10-Q filing.